Trial Subgroup Claims in a Press Release: Matching the Headline to the Protocol

When a press release says a treatment “worked best” in a particular slice of a trial — women over 65, a specific genotype, patients with more severe symptoms at baseline — the headline is describing one piece of the study, not the whole result. This article gives you a short way to test whether that piece can actually support the claim built on top of it, using two questions a trial’s own protocol and statistical methods usually answer: was the subgroup decided on before the data came in, and was it tested with a method built for comparing subgroups, rather than just checked for significance on its own.

What a subgroup claim actually is

Most trials are designed and powered around one main comparison: does the treatment group differ from the control group on a primary outcome measure — the single result the study is built to answer. Trials also track secondary outcome measures, described in trial registries as planned measures that “may provide supportive information about a therapy’s effect on the primary endpoint or demonstrate additional effects.”

A subgroup analysis is a further step: instead of asking whether the treatment worked overall, it asks whether the effect looked different within a smaller slice of participants defined by a characteristic like age, sex, disease severity, or a biomarker. That is a legitimate and common part of clinical research. The question this article is built around is narrower: when a subgroup result becomes the headline of a press release, how much weight can a reader put on it without reading the underlying protocol or publication?

Why subgroup claims in press releases deserve a second look

A cohort study published in PLOS Medicine tracked matched sets of trial journal abstracts, the press releases built from them, and the news coverage that followed. It found distorted reporting — the researchers’ term for it is “spin,” meaning reporting choices that emphasize a beneficial effect beyond what the data support — in 40% of journal abstracts, 47% of press releases, and 51% of news items. Emphasizing subgroup analyses or secondary outcomes while downplaying a nonsignificant primary result was one of the specific patterns the study counted as spin. The same study found that trials with spin in the abstract were 5.6 times more likely to carry spin into the press release, and that readers relying on the press release alone overestimated treatment benefit in 27% of cases.

None of this means a subgroup claim in a press release is wrong. It means a subgroup claim is exactly the kind of statement worth checking before treating it as equivalent to the trial’s main finding.

The headline audit card

Two questions do most of the work when you’re deciding how much a subgroup claim can carry.

1. Was the subgroup prespecified, or found afterward?

Researchers who study when subgroup findings hold up describe an escalating set of credibility markers, including whether the subgroup was planned before randomization based on a prespecified hypothesis, whether it has biological or clinical plausibility, whether only a small number of subgroups were tested rather than many, and whether the analysis accounted for the extra statistical risk that comes from testing multiple subgroups at once (summarized in a clinical research commentary revisiting these criteria). A subgroup that was named in the trial’s registered protocol before the study started sits on much firmer ground than one identified by scanning the results afterward for something that looked interesting.

What to look for in the release or coverage:

• Does the release use the word “prespecified” or “planned” anywhere near the subgroup claim — or does it use “exploratory,” “post hoc,” or no qualifier at all?
• Does the release link to, or does a search of the trial’s registration record turn up, that subgroup listed as an outcome measure before the study began enrolling?
• Is this one subgroup among a handful named in the protocol, or does the release read like it’s highlighting the single best-looking result out of many subgroups that could have been checked?

2. Was it tested as an interaction, or just checked separately in each group?

There are two different ways to report a subgroup finding, and they carry very different weight. One is to test each subgroup on its own — for example, checking whether the treatment beat placebo among women, and separately whether it beat placebo among men. Running several of these separate checks raises the risk of a false positive, since testing multiple times increases the chance that at least one comes back positive just by chance. The other approach is a formal interaction test, which directly asks whether the size of the treatment effect differs between subgroups — not whether each one independently clears a significance threshold. A methodological review in Scientific Reports describes this as the central distinction: an interaction test examines whether the treatment effect differs meaningfully between subgroups, while separate subgroup-specific tests can each be checked for significance without ever formally testing whether the subgroups actually differ from one another.

What to look for:

• Does the release mention a “test for interaction” or an “interaction p-value” — or does it instead just report that a result was significant in one subgroup and not in another?
• If it’s the latter pattern with no interaction test mentioned, that’s a claim resting on a weaker form of subgroup reporting, even if every individual number cited is accurate.

What this card can’t tell you

This checklist screens a claim; it doesn’t settle one. Subgroup analyses are a standard and sometimes important part of drug evaluation — an FDA review of subgroup analyses in recent drug submissions notes that they are common practice and have, in some cases, revealed genuine efficacy or safety differences in specific subpopulations that affected regulatory decisions. The same review also flags that subgroup analyses can be improperly conducted, misreported, or misinterpreted. Neither the press release nor this card can substitute for reading the actual statistical methods section of the published study or the registered protocol — the card just tells you which of those documents to go pull, and why.

The next practical step

If a press release builds its headline around a subgroup result, look up the trial’s own public registration record — most interventional trials are registered at ClinicalTrials.gov. Check whether the subgroup in question appears among that trial’s listed outcome measures, rather than only in the press release. If a full study publication exists, its statistics section will typically say directly whether the subgroup analysis was prespecified and whether an interaction test was used. If none of that is available or confirmable, the reasonable default is to treat the subgroup claim as exploratory — worth noting, not yet worth treating as established.

For more on how trial results are reported and where they commonly get overstated, see our Safety & Limitations coverage. This card is a tool for evaluating how a subgroup claim is presented — it does not evaluate whether any treatment is safe or effective, and it is not a substitute for discussing a specific trial result with a treating clinician.